Robert Tchelepi
About Robert Tchelepi
Robert Tchelepi is a Scientist II at Bolt Biotherapeutics, Inc., specializing in mass spectrometry and analytical method development. He has a background in biotechnology and pharmacology, with experience at several prominent research institutions including Genentech and AbbVie.
Work at Bolt Biotherapeutics
Robert Tchelepi has been employed at Bolt Biotherapeutics, Inc. as a Scientist II since 2019. In this role, he manages Contract Research Organizations (CROs) for analytical method development and characterization. His work includes developing LCMS peptide map workflows that focus on site conjugation and Post Translational Modifications (PTM) analysis, which are critical for characterization and comparability studies.
Education and Expertise
Robert Tchelepi studied at the University of California, Santa Barbara, where he earned a Bachelor’s Degree in Pharmacology from 2012 to 2015. He also attended Foothill College, achieving a degree in Biotechnology from 2009 to 2012. His educational background provides a strong foundation for his expertise in mass spectrometry and analytical development.
Background in Research and Development
Robert Tchelepi has a diverse background in research and development within the biotechnology sector. He worked at Genentech as a Research Associate from 2016 to 2017 and at Antibody Solutions as a Research Associate from 2015 to 2016. His earlier experiences include internships at Stanford University in 2015 and iCRco in 2014, where he gained valuable insights into chemical engineering and research methodologies.
Achievements in Mass Spectrometry
During his tenure at AbbVie as Associate Scientist II - Mass Spectrometry from 2017 to 2019, Robert Tchelepi developed intact mass spectrometry workflows that were essential for determining Drug to Antibody ratios and assessing the integrity of antibody-drug conjugates (ADCs) and Immuno Stimulating Antibody Conjugates (ISACs). He also authored the IND Elucidation of Structure Section for Module 3 for a novel ISAC.